title: NKT ligand-loaded, antigen-expressing B cells function as long-lasting antigen presenting cells in vivo.
abstract: We had previously shown that activated NKT cells licensed B cells to be immunogenic antigen-presenting cells and helped to elicit a wide spectrum of cancer targeted immune responses. In the current study, we sought to verify the safety of αGalCer-loaded, and adenovirus-transduced B cell-based vaccines, together with mechanism of action. Intravenously injected αGalCer-loaded, antigen-expressing B cells rapidly localized in the spleen and directly primed CD8(+) T cells in an antigen-specific manner. The transferred antigen was sustained for at least 30 days. While some injected B cells produced nonspecific IgG, the antigen-specific IgG response was completely dependent on endogenous B cells. The liver was one of the main tissues where injected B cells were retained; however, we could not find the signs of liver toxicity. Our results demonstrate that αGalCer-loaded, antigen-expressing B cells behave as "antigen-presenting" cells that stimulate endogenous antigen-specific T cells and B cells in vivo without significant toxicity.
authors: Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
authors: Yeon-Jeong
authors: YJ
authors: Kim
authors: Seung-Hee
authors: SH
authors: Han
authors: Ho-Woong
authors: HW
authors: Kang
authors: Jung-Mi
authors: JM
authors: Lee
authors: Yun-Sun
authors: YS
authors: Kim
authors: Jeong-Hwan
authors: JH
authors: Seo
authors: Yun-Kyeong
authors: YK
authors: Seong
authors: Hyun-Jeong
authors: HJ
authors: Ko
authors: Tae Hyun
authors: TH
authors: Choi
authors: Cheol
authors: C
authors: Moon
authors: Chang-Yuil
authors: CY
authors: Kang
mesh_terms: D000256:Adenoviridae / Q000235:genetics / Q000276:immunology; D000818:Animals; D000918:Antibody Specificity; D000938:Antigen-Presenting Cells / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology* / Q000637:transplantation; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology* / Q000633:toxicity; D005699:Galactosylceramides / Q000008:administration & dosage / Q000276:immunology; D007074:Immunoglobulin G / Q000096:biosynthesis; D016233:Immunotherapy, Active; D008024:Ligands; D008099:Liver / Q000276:immunology; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D055611:Natural Killer T-Cells / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D013154:Spleen / Q000276:immunology; D014162:Transfection
chemical_list: D019496:Cancer Vaccines; D005699:Galactosylceramides; D007074:Immunoglobulin G; D008024:Ligands; C493154:alpha-galactosylceramide